Pavlidis Efstathios T, Lambropoulou Maria, Symeonidis Nikolaos G, Anagnostopoulos Constantinos, Tsaroucha Alexandra, Kotini Athanasia, Nikolaidou Christina, Kiziridou Anastasia, Simopoulos Constantinos
c 2nd Department of Surgery and Laboratory of Experimental Surgery - Postgraduate Program in Hepatobiliary/Pancreatic Surgery, School of Medicine , Democritus University of Thrace , 68 100 Alexandroupolis , Greece.
a Laboratories of Histology-Embryology.
J Invest Surg. 2018 Apr;31(2):142-150. doi: 10.1080/08941939.2017.1280565. Epub 2017 Feb 10.
Purpose/aim: To examine with immunohistochemical assay MTA1 protein expression levels in pancreatic cancer tissues defining its prognostic value.
The specimens derived from 51 patients who underwent surgery. The levels of MTA1 protein were compared with the age of the patients, their survival, and prognosis. Also, we studied clinical and histopathological factors such as the degree of tumor differentiation and its stage in correlation with MTA1 protein levels. In parallel, there was correlation between the expression of the ΜΤΑ1 protein and the aforementioned factors regarding survival rate. Furthermore, we independently correlated the patient's survival in relation to whether they had undergone adjuvant chemotherapy or not.
It has been found to be low, moderate, or high expression of MTA1 levels in 48 out of 51 cancer tissues. Specifically, 49.0% of patients had low expression, 33.3% moderate, and 11.8% high expression of MTA1. Regarding the expression of MTA1 protein in correlation with various clinical and histopathological factors, a statistically significant correlation was observed with the degree of differentiation (p = 0.0068) and with the stage of the disease (p = 0.0173), but not with survival (p = 0.0740) or the age of them (p = 0.1547). Finally, it was found that overexpression of the MTA1protein is a prognostic factor for shorter survival in patients with pancreatic cancer (average 4.67 ± 0.95 months).
MTA 1 protein may constitute an important prognostic marker in pancreatic cancer and could improve prognosis and treatment.
目的/目标：通过免疫组织化学分析检测胰腺癌组织中MTA1蛋白的表达水平，确定其预后价值。
标本取自51例接受手术的患者。将MTA1蛋白水平与患者年龄、生存情况及预后进行比较。此外，我们研究了肿瘤分化程度和疾病分期等临床和组织病理学因素与MTA1蛋白水平的相关性。同时，MTA1蛋白的表达与上述生存率相关因素之间存在相关性。此外，我们还独立分析了患者是否接受辅助化疗与生存情况的关系。
在51个癌组织中的48个中发现MTA1水平呈低、中或高表达。具体而言，49.0%的患者MTA1表达低，33.3%中等，11.8%高表达。关于MTA1蛋白表达与各种临床和组织病理学因素的相关性，观察到与分化程度（p = 0.0068）和疾病分期（p = 0.0173）有统计学显著相关性，但与生存率（p = 0.0740）或患者年龄（p = 0.1547）无关。最后发现，MTA1蛋白过表达是胰腺癌患者生存时间缩短的一个预后因素（平均4.67±0.95个月）。
MTA1蛋白可能是胰腺癌的一个重要预后标志物，可改善预后和治疗。
